The aims of the UCSF-GIVI CFAR are to support a multi-disciplinary environment that promotes basic, clinical, epidemiologic, behavioral, and translational research in the prevention, detection, and treatment of HIV infection and AIDS and to further the programs of NIH institutes by providing unique and effectively managed activities propelling HIV research. CFAR applies effective leadership, open communications, educational opportunities, sound resource management, and strategic planning to link CFAR members across sites and scientific disciplines. The Center's leadership is committed to proactive management, transparency and continued program monitoring, evaluation, and readjustment. CFAR maintains an effective partnership with the UCSF AIDS Research Institute and with the Center for AIDS Prevention Studies. To catalyze multidisciplinary research, the Center manages six scientific cores (Clinical and Population Sciences, Immunology, Virology, Specimen Banking, Pharmacology, and International). The Clinical and Population Sciences Core facilitates access to appropriate clinical cohorts. The International Core, focused on a growing portfolio in Uganda, will build in-country capacity and collaborate with the Fogarty International Center in training. Expansion to other African sites is expected. Core Directors are charged with member outreach and soliciting new investigators to take advantage of the cutting edge technologies and assays available within the cores. Success of the scientific cores is assessed by the quality of the multidisciplinary science they stimulate and by the publications and successful grants to which they contribute. The CFAR Administrative Core maintains an electronic network, including videoconferencing, to connect and inform all CFAR members, organizes scientific seminars and symposia, and implements financial systems to monitor and report all CFAR funds, ensuring maximum CFAR effectiveness. The Developmental Core funds pilot and basic science grants. It supports the next generation of HIV science through mentored pilot grants and an extremely successful and ambitious formal mentoring program. The success of the UCSF-GIVI CFAR is evident in the scientific accomplishments of its investigators, its ability to galvanize fundamentally new science through its focus on innovative multidisciplinary HIV research, and the significant institutional support it receives from UCSF, the San Francisco Veterans Affairs Medical Center and the J. David Gladstone Institutes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027763-20
Application #
8133776
Study Section
Special Emphasis Panel (ZAI1-EC-A (J1))
Program Officer
Namkung, Ann S
Project Start
1997-03-01
Project End
2012-08-31
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
20
Fiscal Year
2011
Total Cost
$3,120,279
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Tymejczyk, Olga; Brazier, Ellen; Yiannoutsos, Constantin et al. (2018) HIV treatment eligibility expansion and timely antiretroviral treatment initiation following enrollment in HIV care: A metaregression analysis of programmatic data from 22 countries. PLoS Med 15:e1002534
Sauceda, John A; Lisha, Nadra E; Neilands, Torsten B et al. (2018) Cognitive-affective depressive symptoms and substance use among Latino and non-Latino White patients in HIV care: an analysis of the CFAR network of integrated clinical systems cohort. J Behav Med :
Carrico, Adam W; Cherenack, Emily M; Roach, Margaret E et al. (2018) Substance-associated elevations in monocyte activation among methamphetamine users with treated HIV infection. AIDS 32:767-771
AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord (2018) Non-Hodgkin lymphoma risk in adults living with HIV across five continents. AIDS 32:2777-2786
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Mwimanzi, Francis; Toyoda, Mako; Mahiti, Macdonald et al. (2018) Resistance of Major Histocompatibility Complex Class B (MHC-B) to Nef-Mediated Downregulation Relative to that of MHC-A Is Conserved among Primate Lentiviruses and Influences Antiviral T Cell Responses in HIV-1-Infected Individuals. J Virol 92:
Krarup, A R; Abdel-Mohsen, M; Schleimann, M H et al. (2018) The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon. Mucosal Immunol 11:449-461
Shipley, Mackenzie M; Renner, Daniel W; Ott, Mariliis et al. (2018) Genome-Wide Surveillance of Genital Herpes Simplex Virus Type 1 From Multiple Anatomic Sites Over Time. J Infect Dis 218:595-605
Howe, Chanelle J; Dulin-Keita, Akilah; Cole, Stephen R et al. (2018) Evaluating the Population Impact on Racial/Ethnic Disparities in HIV in Adulthood of Intervening on Specific Targets: A Conceptual and Methodological Framework. Am J Epidemiol 187:316-325
Sanford, Ryan; Ances, Beau M; Meyerhoff, Dieter J et al. (2018) Longitudinal Trajectories of Brain Volume and Cortical Thickness in Treated and Untreated Primary Human Immunodeficiency Virus Infection. Clin Infect Dis 67:1697-1704

Showing the most recent 10 out of 1541 publications